In the CARDS trial, atorvastatin reduced major cardiovascular events by 37% compared with placebo in patients with type 2 diabetes and no prior cardiovascular disease. Despite that evidence, registry data show 59.2% of statin-eligible adults not on therapy reported that no clinician had ever offered it to them. The D12 measure has a 2026 national numeric average of 88% for MA-PD contracts, and because a single qualifying Part D pharmacy claim satisfies the entire numerator, the gap between eligibility and credit is usually a prescribing and dispensing-pathway problem rather than a clinical one.
AAVBC's Statin Use in Persons with Diabetes (SUPD) Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering the measure specification and PDE-only data source, denominator triggers and index prescription start dates, exclusion diagnoses and billing codes, cut points and industry performance, high-yield prescribing interventions, statin intolerance and adherence barriers, disparity gaps requiring targeted action, and documentation that supports care. Grounded in current ADA and PQA guidance, this guide supports consistent, individualized clinical decision-making, helping care teams start and sustain statin therapy where benefit is clearly established, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of D12 performance — moving far beyond quick-reference essentials. These guides provide an integrated review of measurement importance and impact, clinical integrations, technical details, challenges and barriers, strategies for team coordination and quality improvement as well as regulatory and financial considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of D12 performance and provide care teams with strategies to thrive within a value-based model.
In the CARDS trial, atorvastatin reduced major cardiovascular events by 37% compared with placebo in patients with type 2 diabetes and no prior cardiovascular disease. Despite that evidence, registry data show 59.2% of statin-eligible adults not on therapy reported that no clinician had ever offered it to them. The D12 measure has a 2026 national numeric average of 88% for MA-PD contracts, and because a single qualifying Part D pharmacy claim satisfies the entire numerator, the gap between eligibility and credit is usually a prescribing and dispensing-pathway problem rather than a clinical one.
AAVBC's Statin Use in Persons with Diabetes (SUPD) Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering the measure specification and PDE-only data source, denominator triggers and index prescription start dates, exclusion diagnoses and billing codes, cut points and industry performance, high-yield prescribing interventions, statin intolerance and adherence barriers, disparity gaps requiring targeted action, and documentation that supports care. Grounded in current ADA and PQA guidance, this guide supports consistent, individualized clinical decision-making, helping care teams start and sustain statin therapy where benefit is clearly established, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of D12 performance — moving far beyond quick-reference essentials. These guides provide an integrated review of measurement importance and impact, clinical integrations, technical details, challenges and barriers, strategies for team coordination and quality improvement as well as regulatory and financial considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of D12 performance and provide care teams with strategies to thrive within a value-based model.
